Successful booster antibody response up to 54 months after single primary vaccination with virosome-formulated, aluminum-free hepatitis A vaccine.
This study demonstrates that a booster dose of the virosome-formulated, aluminum-free hepatitis A vaccine Epaxal (Berna Biotech) is highly immunogenic in subjects who received a single primary dose of this vaccine 18-54 months earlier. There were no significant differences in geometric mean antibody titers (GMTs) among subjects who received the booster dose 18-29 months (GMT, 2330 mIU/mL), 30-41 months (GMT, 2395 mIU/mL), or 42-54 months (GMT, 2432 mIU/mL) after primary vaccination, indicating that delays in the administration of booster vaccination do not lead to a loss of immunogenicity.
Beck
Bernhard R
BR
Swiss Tropical Institute, Basel, Switzerland. bernhard.beck@unibas.ch
Hatz
Christoph
C
Brönnimann
Rainer
R
Herzog
Christian
C
D000328:Adult; D000368:Aged; D000535:Aluminum / Q000378:metabolism; D005260:Female; D006506:Hepatitis A / Q000276:immunology* / Q000517:prevention & control; D022362:Hepatitis A Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary; D008297:Male; D008875:Middle Aged; D014195:Travel; D022721:Vaccines, Virosome / Q000008:administration & dosage / Q000276:immunology*
D022362:Hepatitis A Vaccines; D022721:Vaccines, Virosome; D000535:Aluminum